StockData

Artiva Biotherapeutics vs aTYR PHARMA

ARTV and ATYR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ARTV and ATYR compare

aTYR PHARMA is the larger company, worth 2.7 times as much as Artiva Biotherapeutics ($514M against $194M).

Artiva Biotherapeutics scores higher on the StockData Score (8 against 5 for aTYR PHARMA), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricARTVATYR
Size and price
Market cap$194M$514M
Share price$3.96$5.24
Change, 1 year16.8%635%
Change, 5 years–−98.4%
Beta (5Y)4.81–
Employees10458
StockData Score
Total score8 (better)5
Valuation score1 (better)0
Growth score00
Performance score1 (better)0
Health score6 (better)5
Dividend score00
Valuation
P/B0.6× (better)10.5×
FCF yield−39.7%−10.7% (better)
Growth
Revenue growth, 5Y average–−55.1%
Profitability
Return on equity−36.6% (better)−98.4%
Return on invested capital−3203%–
Financial health
Debt / equity0.000.00
Current ratio24.16 (better)5.12
Altman Z-score4.30 (better)−0.26
Piotroski F-score13 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions83.2%41.4%
Held by insiders68.3%2.6%
Insider net buying, 12 months$106M (better)$43.7K
Superinvestors holding1–
Short interest, % of float19.0%0.31%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.